Brian Abrahams is ranked #1476 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Brian Abrahams

RBC

Brian Abrahams

Q: How accurate are Brian Abrahams's stock ratings?

About 56% of Brian's ratings were profitable over a one-year hold, with an average return of +6.5% per rating, measured by 13Foresight from historical prices.

RBC Capital

Wall Street Analyst

★★★☆☆

#1476

on 13Foresight · ranked by our own returns

57%

Success Rate

+6.6%

Average Return

65 of 114 calls profitable · +0.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 57% of Brian Abrahams's ratings turned a profit when each position was held for 1 year — averaging +6.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

148 Buy 115 Hold 5 Sell

Brian's Stock Coverage 65 ratings · 2026-08-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
DMRA Damora Therapeutics	Aug 10, 2026	BUY	Strong Buy -4.7% avg upside 20 analysts	$40.00 31.71% Upside	·	·
SION Sionna Therapeutics, Inc.	Aug 10, 2026	HOLD	Hold +170.0% avg upside 12 analysts	$5.00 1.96% Downside	+16.4%	·
APGE Apogee Therapeutics	Aug 10, 2026	HOLD	Buy -8.0% avg upside 19 analysts	$135.00 0.23% Upside	-0.1%	·
LKFT Lakefront Biotherapeutics	Aug 10, 2026	HOLD	Buy +271.6% avg upside 24 analysts	$26.00 9.59% Downside	·	·
MLTX MoonLake Immunotherapeutics	Aug 10, 2026	HOLD	Strong Buy +75.6% avg upside 20 analysts	$17.00 2.38% Upside	-0.2%	·
NRIX Nurix Therapeutics	Aug 10, 2026	BUY	Strong Buy +24.1% avg upside 28 analysts	$36.00 38.64% Upside	-0.1%	·
ATYR aTyr Pharma	Aug 09, 2026	HOLD	Buy +1473.5% avg upside 17 analysts	$1.00 87.28% Upside	·	·
XENE Xenon	Aug 06, 2026	BUY	Strong Buy -1.9% avg upside 28 analysts	$81.00 28.19% Upside	+0.4%	·
EVMN Evommune, Inc.	Aug 06, 2026	BUY	Strong Buy +168.9% avg upside 12 analysts	$29.00 104.10% Upside	+6.2%	·
GHRS GH Research	Aug 06, 2026	BUY	Strong Buy +35.9% avg upside 12 analysts	$42.00 44.40% Upside	-2.1%	·
DFTX Definium Therapeutics	Aug 06, 2026	BUY	Strong Buy +13.9% avg upside 21 analysts	$57.00 39.38% Upside	-2.1%	·
CRBP Corbus Pharmaceuticals	Aug 06, 2026	BUY	Strong Buy +277.6% avg upside 20 analysts	$36.00 278.56% Upside	+4.4%	·
PRTA Prothena	Aug 06, 2026	HOLD	Buy +152.9% avg upside 14 analysts	$13.00 41.04% Upside	+6.3%	·
SRPT Sarepta Therapeutics	Aug 05, 2026	HOLD	Buy +233.1% avg upside 49 analysts	$19.00 4.33% Upside	+5.3%	·
KYMR Kymera Therapeutics	Aug 05, 2026	HOLD	Strong Buy -3.4% avg upside 37 analysts	$112.00 2.16% Upside	+2.9%	·
BCRX BioCryst	Aug 05, 2026	BUY	Strong Buy +77.6% avg upside 24 analysts	$13.00 25.74% Upside	+3.4%	·
GILD Gilead Sciences	Aug 04, 2026	HOLD	Strong Buy -12.1% avg upside 66 analysts	$123.00 9.43% Downside	-1.6%	·
ACAD ACADIA Pharmaceuticals	Aug 04, 2026	BUY	Strong Buy +24.2% avg upside 43 analysts	$37.00 25.76% Upside	+9.1%	·
VRTX Vertex Pharmaceuticals	Aug 03, 2026	BUY	Strong Buy -15.5% avg upside 62 analysts	$570.00 7.62% Upside	+12.3%	·
KPTI Karyopharm Therapeutics	Jul 31, 2026	BUY	Strong Buy +839.6% avg upside 18 analysts	$8.00 280.86% Upside	+10.4%	·
REGN Regeneron	Jul 30, 2026	HOLD	Strong Buy -2.1% avg upside 58 analysts	$737.00 7.55% Downside	+6.2%	·
CTNM Contineum Therapeutics, Inc. Class A	Jul 30, 2026	BUY	Strong Buy +46.5% avg upside 9 analysts	$23.00 55.18% Upside	-4.5%	·
PTCT PTC Therapeutics	Jul 30, 2026	HOLD	Strong Buy +9.8% avg upside 29 analysts	$85.00 15.35% Upside	-3.5%	·
NBIX Neurocrine	Jul 30, 2026	BUY	Strong Buy +15.6% avg upside 37 analysts	$198.00 22.35% Upside	-11.9%	·
BIIB Biogen	Jul 29, 2026	BUY	Strong Buy +23.5% avg upside 52 analysts	$240.00 17.74% Upside	-0.6%	·
INCY Incyte	Jul 28, 2026	HOLD	Buy -11.2% avg upside 47 analysts	$109.00 10.06% Downside	-7.2%	·
NMRA Neumora Therapeutics, Inc.	Jul 13, 2026	BUY	Buy +357.2% avg upside 11 analysts	$5.00 194.05% Upside	+0.0%	·
PLRX Pliant Therapeutics	May 11, 2026	HOLD	Buy +2060.2% avg upside 21 analysts	$2.00 94.25% Upside	-12.5%	·
AARD Aardvark Therapeutics, Inc.	May 07, 2026	HOLD	Buy +145.7% avg upside 12 analysts	$6.00 16.65% Downside	+41.1%	·
MIRM Mirum Pharmaceuticals	Apr 07, 2026	BUY	Strong Buy +14.8% avg upside 22 analysts	$128.00 30.37% Upside	+3.2%	·
TSE:SOBO South Bow Corp	Oct 26, 2025	BUY	Hold -6.6% avg upside 20 analysts	$39.00 22.75% Downside	+42.5%	·
ENTA Enanta Pharmaceuticals	Oct 02, 2023	HOLD	Buy +142.0% avg upside 17 analysts	$15.00 10.99% Upside	+7.2%	·
VERX Vertex	Oct 28, 2022	HOLD	Buy +170.6% avg upside 24 analysts	$288.00 2254.92% Upside	+27.8%	·
ATAI Atai Beckley N.V.	May 16, 2022	HOLD	Buy +39.1% avg upside 17 analysts	$8.00 10.94% Upside	-52.0%	·
OVID Ovid Therapeutics	Aug 16, 2021	HOLD	Strong Buy +95.3% avg upside 18 analysts	$4.00 55.09% Upside	-41.2%	·
AMGN Amgen	Oct 26, 2017	HOLD	Buy -23.9% avg upside 57 analysts	$188.00 54.59% Downside	+8.4%	·
ABEO Abeona Therapeutics	Sep 15, 2017	BUY	Strong Buy +130.1% avg upside 17 analysts	$23.00 210.82% Upside	·	·
CVX Chevron	May 17, 2017	BUY	Strong Buy -5.2% avg upside 44 analysts	$135.00 31.45% Downside	+28.4%	·
RARE Ultragenyx Pharmaceutical	May 08, 2017	HOLD	Strong Buy +147.0% avg upside 36 analysts	$68.00 152.21% Upside	-3.8%	·
OSK Oshkosh	Apr 27, 2017	BUY	Strong Buy -7.1% avg upside 28 analysts	$80.00 48.59% Downside	+3.1%	·
FE FirstEnergy	Mar 31, 2017	HOLD	Buy +4.2% avg upside 25 analysts	$32.00 31.58% Downside	+12.0%	·
ARCT Arcturus Therapeutics	Mar 31, 2017	HOLD	Buy +295.4% avg upside 36 analysts	$8.75 16.28% Upside	-31.1%	·
PEG Public Service Enterprise	Mar 31, 2017	HOLD	Buy +11.3% avg upside 32 analysts	$46.50 38.10% Downside	+17.5%	·
QURE uniQure	Mar 07, 2017	HOLD	Strong Buy +31.2% avg upside 29 analysts	$8.00 82.14% Downside	+345.4%	·
AFMDQ Affimed	Feb 16, 2017	HOLD	Buy +14226263.6% avg upside 16 analysts	$2.50 2499900.00% Upside	·	·
DBVT DBV Technologies SA - American	Feb 09, 2017	BUY	Buy +70.4% avg upside 15 analysts	$47.00 233.52% Upside	-36.6%	·
HAE Haemonetics	Jan 05, 2017	BUY	Buy -13.7% avg upside 17 analysts	$42.00 51.93% Downside	+59.1%	·
CLDX Celldex	Nov 23, 2016	HOLD	Strong Buy -6.9% avg upside 28 analysts	$5.00 88.65% Downside	-34.0%	·
RRC Range Resources	Nov 16, 2016	BUY	Buy -6.9% avg upside 43 analysts	$46.00 13.19% Upside	-49.8%	·
CMCSA Comcast	Nov 16, 2016	BUY	Buy +50.8% avg upside 42 analysts	$38.50 50.03% Upside	+11.7%	·
CVS CVS Health	Nov 01, 2016	BUY	Strong Buy +12.8% avg upside 39 analysts	$122.00 30.41% Upside	-15.2%	·
BMRN BioMarin Pharmaceutical	Sep 07, 2016	BUY	Strong Buy +36.7% avg upside 52 analysts	$120.00 72.55% Upside	-5.9%	·
TEVA Teva Pharmaceutical	Aug 25, 2016	BUY	Buy -17.3% avg upside 39 analysts	—	-67.2%	·
ABBV AbbVie	Aug 25, 2016	BUY	Strong Buy -4.3% avg upside 46 analysts	—	+16.4%	·
BMY Bristol-Myers Squibb	Aug 22, 2016	HOLD	Buy -4.4% avg upside 42 analysts	—	+0.1%	·
AGEN Agenus	Aug 08, 2016	BUY	Strong Buy +29.8% avg upside 18 analysts	—	·	·
LLY Eli Lilly & Co	Aug 08, 2016	BUY	Strong Buy -13.8% avg upside 48 analysts	—	+3.1%	·
JNJ Johnson & Johnson	Aug 01, 2016	HOLD	Strong Buy -9.2% avg upside 39 analysts	—	+8.5%	·
PFE Pfizer	Jul 15, 2016	BUY	Buy +25.8% avg upside 45 analysts	—	-5.6%	·
CLLS Cellectis SA	Jul 15, 2016	BUY	Strong Buy +601.9% avg upside 16 analysts	—	+8.1%	·
MRK Merck & Company	Jul 15, 2016	HOLD	Strong Buy -0.7% avg upside 43 analysts	—	+8.9%	·
NVS Novartis	Apr 21, 2016	BUY	Hold -14.0% avg upside 24 analysts	$60.50 60.79% Downside	-0.2%	·
RIGL Rigel	Feb 23, 2015	HOLD	Strong Buy -41.4% avg upside 17 analysts	—	-28.2%	·
PLX Protalix	Jun 25, 2012	HOLD	Buy +243.0% avg upside 4 analysts	—	·	·
NVAX Novavax	Sep 02, 2009	HOLD	Hold +190.5% avg upside 20 analysts	—	-60.9%	·

🔒 60 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Brian Abrahams — Frequently Asked Questions

How accurate are Brian Abrahams's stock ratings?

Based on the calls 13Foresight could measure, about 56% of Brian's ratings were profitable over a one-year hold, with an average return of +6.5% per rating, or +0.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Brian ranked on 13Foresight?

Brian Abrahams is currently ranked #1476 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Brian cover?

Brian most recently has ratings on DMRA, SION, APGE, LKFT, MLTX, NRIX, ATYR, XENE, EVMN, GHRS, DFTX, CRBP and 53 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Brian Abrahams

Rating Distribution

Welcome to 13Foresight!